Oncolytic vaccinia virus for the treatment of cancer

Expert Opinion on Biological Therapy

Volumn 11, Issue 5, 2011, Pages 595-608

  Guse, Kilian ^a   Cerullo, Vincenzo ^b,c   Hemminki, Akseli ^b,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

cancer; JX 594; oncolytic virus; vaccinia virus

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; GEMCITABINE; GLV 1H107; GLV 1H108; GLV 1H109; GLV 1H68; GLV 1H99; JX 594; JX 929; JX 963; ONCOLYTIC ADENOVIRUS; ONCOLYTIC HERPES VIRUS; ONCOLYTIC VACCINIA VIRUS; ONCOLYTIC VIRUS; PACLITAXEL; RAPAMYCIN; SORAFENIB; UNCLASSIFIED DRUG; VACCINIA ONCOLYSATE;

ANTINEOPLASTIC ACTIVITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CHILL; CLINICAL TRIAL (TOPIC); COLORECTAL CARCINOMA; COLORECTAL TUMOR; CONGESTIVE CARDIOMYOPATHY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; FLU LIKE SYNDROME; GENE DELETION; GENE EXPRESSION; GENE THERAPY; GLIOMA; HEART ARRHYTHMIA; HUMAN; HYPERBILIRUBINEMIA; HYPERTHERMIC THERAPY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; INFLAMMATION; INJECTION SITE PAIN; KIDNEY CANCER; LIVER CANCER; LIVER CELL CARCINOMA; LIVER METASTASIS; LOW DRUG DOSE; LUNG CANCER; LUNG METASTASIS; MALAISE; MAXIMUM TOLERATED DOSE; MELANOMA; MULTIPLE MYELOMA; MYOCARDITIS; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PERICARDITIS; REVIEW; SKIN INFLAMMATION; SKIN MANIFESTATION; THROMBOCYTOPENIA; TRANSGENE; TREATMENT RESPONSE; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME; VIRUS REPLICATION; VIRUS STRAIN;

COMBINED MODALITY THERAPY; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; VACCINIA VIRUS;

VACCINIA VIRUS;

EID: 79953865759     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.558838     Document Type: Review

References (116)

1. Smith GL, Vanderplasschen A, Law M. The formation and function of extracellular enveloped vaccinia virus. J Gen Virol 2002;83(Pt 12):2915-31 (Pubitemid 36054337)
2. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 1996;93(21):11341-8 (Pubitemid 26347123)
3. Fenner F. A successful eradication campaign. Global eradication of smallpox. Rev Infect Dis 1982;4(5):916-30
4. Shen Y, Nemunaitis J. Fighting cancer with vaccinia virus: teaching new tricks to an old dog. Mol Ther 2005;11(2):180-95 (Pubitemid 40163961)
5. Smith GL, Murphy BR, Moss B. Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc Natl Acad Sci USA 1983;80(23):7155-9 (Pubitemid 14207373)
6. Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001;292(5514):69-74 (Pubitemid 32289126)
7. Miller JD, van der Most RG, Akondy RS, et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 2008;28(5):710-22
8. Putz MM, Midgley CM, Law M, et al. Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination. Nat Med 2006;12(11):1310-15 (Pubitemid 44706934)
9. McFadden G. Poxvirus tropism. Nat Rev Microbiol 2005;3(3):201-13 (Pubitemid 40298220)
10. Moss B. Poxviridae: the viruses and their replication. Fields virology. 5th edition; 2007
11. Wittek R Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy. Int J Infect Dis 2006;10(3):193-201
12. De Clercq E. Cidofovir in the treatment of poxvirus infections. Antiviral Res 2002;55(1):1-13 (Pubitemid 34655638)
13. Yang G, Pevear DC, Davies MH, et al. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J Virol 2005;79(20):13139-49 (Pubitemid 41433232)
14. Reeves PM, Bommarius B, Lebeis S, et al. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat Med 2005;11(7):731-9 (Pubitemid 41021205)
15. Smith GL, Moss B. Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. Gene 1983;25(1):21-8 (Pubitemid 14241202)
16. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10(9):909-15 (Pubitemid 39273730)
17. Acres B, Bonnefoy JY. Clinical development of MVA-based therapeutic cancer vaccines. Expert Rev Vaccines 2008;7(7):889-93
18. Rosenthal R, Viehl CT, Guller U, et al. Active specific immunotherapy phase III trials for malignant melanoma: systematic analysis and critical appraisal. J Am Coll Surg 2008;207(1):95-105
19. Amato RJ. 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy. Expert Opin Biol Ther 2010;10(2):281-7
20. Lee SS, Eisenlohr LC, McCue PA, et al. Intravesical gene therapy: in vivo gene transfer using recombinant vaccinia virus vectors. Cancer Res 1994;54(13):3325-8 (Pubitemid 24225940)
21. Timiryasova TM, Chen B, Haghighat P, et al. Vaccinia virus-mediated expression of wild-type p53 suppresses glioma cell growth and induces apoptosis. Int J Oncol 1999;14(5):845-54
22. Timiryasova TM, Li J, Chen B, et al. Antitumor effect of vaccinia virus in glioma model. Oncol Res 1999;11(3): 133-44
23. Timiryasova TM, Chen B, Fodor I. Replication-deficient vaccinia virus gene therpay vector: evaluation of exogenous gene expression mediated by PUV-inactivated virus in glioma cells. J Gene Med 2001;3(5):468-77 (Pubitemid 33684783)
24. Erbs P, Findeli A, Kintz J, et al. Modified vaccinia virus Ankara as a vector for suicide gene therapy. Cancer Gene Ther 2008;15(1):18-28 (Pubitemid 350261298)
25. Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 2009;9(1):64-71
26. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005;5(4):331-42 (Pubitemid 40516158)
27. Rubartelli A, Lotze MT. Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol 2007;28(10):429-36 (Pubitemid 47444554)
28. Zhu J, Martinez J, Huang X, et al. Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta. Blood 2007;109(2):619-25 (Pubitemid 46105962)
29. Breitbach CJ, Paterson JM, Lemay CG, et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther 2007;15(9):1686-93 (Pubitemid 47289013)
30. Liu TC, Hwang T, Park BH, et al. The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther 2008;16(9):1637-42
31. Zeh HJ, Bartlett DL. Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers. Cancer Gene Ther 2002;9(12):1001-12 (Pubitemid 35462562)
32. Vanderplasschen A, Mathew E, Hollinshead M, et al. Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc Natl Acad Sci USA 1998;95(13):7544-9 (Pubitemid 28293289)
33. Bell E, Shamim M, Whitbeck JC, et al. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology 2004;325(2):425-31 (Pubitemid 38902805)
34. Whitman ED, Tsung K, Paxson J, et al. In vitro and in vivo kinetics of recombinant vaccinia virus cancer-gene therapy. Surgery 1994;116(2):183-8 (Pubitemid 24260706)
35. Puhlmann M, Brown CK, Gnant M, et al. Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther 2000;7(1):66-73 (Pubitemid 30080989)
36. Peplinski GR, Tsung AK, Casey MJ, et al. In vivo murine tumor gene delivery and expression by systemic recombinant vaccinia virus encoding interleukin-1beta. Cancer J Sci Am 1996;2(1):21-7
37. McCart JA, Ward JM, Lee J, et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 2001;61(24):8751-7 (Pubitemid 34013887)
38. Buller RM, Smith GL, Cremer K, et al. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 1985;317(6040):813-15 (Pubitemid 16195408)
39. Gnant MF, Noll LA, Irvine KR, et al. Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases. J Natl Cancer Inst 1999;91(20):1744-50 (Pubitemid 29518770)
40. Tzahar E, Moyer JD, Waterman H, et al. Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network. EMBO J 1998;17(20):5948-63 (Pubitemid 28474789)
41. de Magalhaes JC, Andrade AA, Silva PN, et al. A mitogenic signal triggered at an early stage of vaccinia virus infection: implication of MEK/ERK and protein kinase A in virus multiplication. J Biol Chem 2001;276(42):38353-60
42. Thorne SH, Hwang TH, O'Gorman WE, et al. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Invest 2007;117(11):3350-8 (Pubitemid 350096991)
43. Zhang Q, Yu YA, Wang E, et al. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res 2007;67(20):10038-46 (Pubitemid 47621255)
44. Taylor JM, Quilty D, Banadyga L, et al. The vaccinia virus protein F1L interacts with Bim and inhibits activation of the pro-apoptotic protein Bax. J Biol Chem 2006;281(51):39728-39 (Pubitemid 46041932)
45. Gnant MF, Puhlmann M, Alexander HR Jr, et al. Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice. Cancer Res 1999;59(14):3396-403 (Pubitemid 29334499)
46. McCart JA, Puhlmann M, Lee J, et al. Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression. Gene Ther 2000;7(14):1217-23 (Pubitemid 30488768)
47. Foloppe J, Kintz J, Futin N, et al. Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus. Gene Ther 2008;15(20):1361-71
48. Guse K, Sloniecka M, Diaconu I, et al. Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models. J Virol 2010;84(2):856-66
49. Frentzen A, Yu YA, Chen N, et al. Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. Proc Natl Acad Sci USA 2009;106(31):12915-20
50. Perera LP, Goldman CK, Waldmann TA. Comparative assessment of virulence of recombinant vaccinia viruses expressing IL-2 and IL-15 in immunodeficient mice. Proc Natl Acad Sci USA 2001;98(9):5146-51 (Pubitemid 32397097)
51. Ruby J, Bluethmann H, Aguet M, et al. CD40 ligand has potent antiviral activity. Nat Med 1995;1(5):437-41
52. Sambhi SK, Kohonen-Corish MR, Ramshaw IA. Local production of tumor necrosis factor encoded by recombinant vaccinia virus is effective in controlling viral replication in vivo. Proc Natl Acad Sci USA 1991;88(9):4025-9 (Pubitemid 21916757)
53. Gherardi MM, Ramirez JC, Rodriguez D, et al. IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner. J Immunol 1999;162(11):6724-33 (Pubitemid 29309398)
54. Lee JH, Roh MS, Lee YK, et al. Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model. Cancer Gene Ther 2010;17(2):73-9
55. Zhang Q, Liang C, Yu YA, et al. The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation. Mol Genet Genomics 2009;282(4):417-35
56. Lin SF, Yu Z, Riedl C, et al. Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus. Surgery 2007;142(6):976-83, discussion 76-83 (Pubitemid 350193250)
57. Kelly KJ, Woo Y, Brader P, et al. Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma. Hum Gene Ther 2008;19(8):774-82
58. Yu YA, Galanis C, Woo Y, et al. Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68. Mol Cancer Ther 2009;8(1):141-51
59. Gentschev I, Donat U, Hofmann E, et al. Regression of human prostate tumors and metastases in nude mice following treatment with the recombinant oncolytic vaccinia virus GLV-1h68. J Biomed Biotechnol 2010;2010:489759
60. Chen N, Zhang Q, Yu YA, et al. A novel recombinant vaccinia virus expressing the human norepinephrine transporter retains oncolytic potential and facilitates deep-tissue imaging. Mol Med 2009;15(5-6):144-51
61. Dranoff G. GM-CSF-based cancer vaccines. Immunol Rev 2002;188:147-54 (Pubitemid 35398872)
62. Degli-Esposti MA, Smyth MJ. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol 2005;5(2):112-24 (Pubitemid 40208901)
63. Bristol JA, Zhu M, Ji H, et al. In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF. Mol Ther 2003;7(6):755-64 (Pubitemid 36790252)
64. Cerullo V, Pesonen S, Diaconu I, et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res 2010;70(11):4297-309
65. Koski A, Kangasniemi L, Escutenaire S, et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther 2010;18(10):1874-84
66. Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003;10(4):292-303 (Pubitemid 36305598)
67. Mastrangelo MJ, Maguire HC Jr, Eisenlohr LC, et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 1999;6(5):409-22 (Pubitemid 129667814)
68. Shanafelt AB, Johnson KE, Kastelein RA. Identification of critical amino acid residues in human and mouse granulocyte-macrophage colony-stimulating factor and their involvement in species specificity. J Biol Chem 1991;266(21):13804-10 (Pubitemid 21907423)
69. Kim JH, Oh JY, Park BH, et al. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther 2006;14(3):361-70 (Pubitemid 44184970)
70. Huang B, Sikorski R, Kirn DH, et al. Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1. Gene Ther 2011;18:164-72
71. Ottolino-Perry K, Diallo JS, Lichty BD, et al. Intelligent design: combination therapy with oncolytic viruses. Mol Ther 2010;18(2):251-63
72. Lun XQ, Jang JH, Tang N, et al. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. Clin Cancer Res 2009;15(8):2777-88
73. Gridley DS, Andres ML, Li J, et al. Evaluation of radiation effects against C6 glioma in combination with vaccinia virus-p53 gene therapy. Int J Oncol 1998;13(5):1093-8 (Pubitemid 28506083)
74. Timiryasova TM, Gridley DS, Chen B, et al. Radiation enhances the anti-tumor effects ofvaccinia-p53 gene therapy in glioma. Technol Cancer Res Treat 2003;2(3):223-35 (Pubitemid 37121886)
75. McCart JA, Mehta N, Scollard D, et al. Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: molecular imaging after systemic delivery using 111In-pentetreotide. Mol Ther 2004;10(3):553-61 (Pubitemid 39186116)
76. Le Boeuf F, Diallo JS, McCart JA, et al. Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther 2010;18(5):888-95
77. Zhang YQ, Tsai YC, Monie A, et al. Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy. Mol Ther 2010;18(4):692-9
78. Cope DA, Dewhirst MW, Friedman HS, et al. Enhanced delivery of a monoclonal antibody F(ab')2 fragment to subcutaneous human glioma xenografts using local hyperthermia. Cancer Res 1990;50(6):1803-9 (Pubitemid 20098825)
79. Gaber MH, Wu NZ, Hong K, et al. Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks. Int J Radiat Oncol Biol Phys 1996;36(5):1177-87 (Pubitemid 27014505)
80. Chang E, Chalikonda S, Friedl J, et al. Targeting vaccinia to solid tumors with local hyperthermia. Hum Gene Ther 2005;16(4):435-44 (Pubitemid 40647141)
81. Baronzio G, Gramaglia A, Fiorentini G. Hyperthermia and immunity. A brief overview. In Vivo 2006;20(6A):689-95
82. Willmon C, Harrington K, Kottke T, et al. Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol Ther 2009;17(10):1667-76
83. Lyons M, Onion D, Green NK, et al. Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Mol Ther 2006;14(1):118-28 (Pubitemid 44191831)
84. Thorne SH, Negrin RS, Contag CH. Synergistic antitumor effects of immune cell-viral biotherapy. Science 2006;311(5768):1780-4
85. Wallack MK, Steplewski Z, Koprowski H, et al. A new approach in specific, active immunotherapy. Cancer 1977;39(2):560-4 (Pubitemid 8063519)
86. Iwaki H, Barnavon Y, Bash JA, et al. Vaccinia virus-infected C-C36 colon tumor cell lysates stimulate cellular responses in vitro and protect syngeneic Balb/c mice from tumor cell challenge. J Surg Oncol 1989;40(2):90-6 (Pubitemid 19068417)
87. Wallack MK. Specific tumor immunity produced by the injection of vaccinia viral oncolysates. J Surg Res 1982;33(1):11-6 (Pubitemid 12096122)
88. Sivanandham M, Scoggin SD, Tanaka N, et al. Therapeutic effect of a vaccinia colon oncolysate prepared with interleukin-2-gene encoded vaccinia virus studied in a syngeneic CC-36 murine colon hepatic metastasis model. Cancer Immunol Immunother 1994;38(4):259-64 (Pubitemid 24108737)
89. Ju DW, Cao X, Acres B. Active specific immunotherapy of pulmonary metastasis with vaccinia melanoma oncolysate prepared from granulocyte/ macrophage-colony-stimulating-factor-gene-encoded vaccinia virus. J Cancer Res Clin Oncol 1996;122(12):716-22 (Pubitemid 26393239)
90. Burdick KH. Malignant melanoma treated with vaccinia injections [abstract]. Arch Dermatol 1960;82:438-39
91. Burdick KH, Hawk WA. Vitiligo in a case of vaccinia virus-treated melanoma. Cancer 1964;17:708-12
92. Belisario JC, Milton GW. The experimental local therapy of cutaneous metastases of malignant melanoblastomas with cow pox vaccine or colcemid (demecolcine or omaine). Aust J Dermatol 1961;6:113-18
93. Hunter-Craig I, Newton KA, Westbury G, et al. Use of vaccinia virus in the treatment of metastatic malignant melanoma. Br Med J 1970;2(5708):512-15
94. Roenigk HH Jr, Deodhar S, St Jacques R, et al. Immunotherapy of malignant melanoma with vaccinia virus. Arch Dermatol 1974;109(5):668-73
95. Mastrangelo MJ, Eisenlohr LC, Gomella L, et al. Poxvirus vectors: orphaned and underappreciated. J Clin Invest 2000;105(8):1031-4 (Pubitemid 30217684)
96. Thorne SH, Bartlett DL, Kirn DH. The use of oncolytic vaccinia viruses in the treatment of cancer: a new role for an old ally? Curr Gene Ther 2005;5(4):429-43 (Pubitemid 41052433)
97. Gomella LG, Mastrangelo MJ, McCue PA, et al. Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J Urol 2001;166(4):1291-5 (Pubitemid 32862158)
98. Arakawa S Jr, Hamami G, Umezu K, et al. Clinical trial of attenuated vaccinia virus AS strain in the treatment of advanced adenocarcinoma. Report on two cases. J Cancer Res Clin Oncol 1987;113(1):95-8 (Pubitemid 17017575)
99. Kawa A, Arakawa S. The effect of attenuated vaccinia virus AS strain on multiple myeloma; a case report. Jpn J Exp Med 1987;57(1):79-81 (Pubitemid 17067625)
100. Park BH, Hwang T, Liu TC, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 2008;9(6):533-42
101. Burke J, Stephenson J, Chow L, et al. Demonstration of delivery and antitumoral activity of JX-594, a targeted multi-mechanistic oncolytic poxvirus, following a single intravenous infusion in patients with refractory metastatic cancers. Am Soc Gene Cell Ther (ASGCT) 13th Annual Meeting, 17-22 May 2010, Washington DC, USA. Abstract 33
102. Heo J, Reid T, Lim HY, et al. Randomized phase II clinical trial of intratumoral injection of JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with hepatocellular carcinoma. European Association for the Study of the Liver. Vienna; 2010 ClinicalTrials.gov. US National Institute of Health; 2010
103. Kim EM, Sivanandham M, Stavropoulos CI, et al. Overview analysis of adjuvant therapies for melanoma-a special reference to results from vaccinia melanoma oncolysate adjuvant therapy trials. Surg Oncol 2001;10(1-2):53-9 (Pubitemid 33086840)
104. Wallack MK, Michaelides M. Serologic response to human melanoma lines from patients with melanoma undergoing treatment with vaccinia melanoma oncolysates. Surgery 1984;96(4):791-800 (Pubitemid 14019728)
105. Wallack MK, McNally KR, Leftheriotis E, et al. A Southeastern Cancer Study Group phase I/II trial with vaccinia melanoma oncolysates. Cancer 1986;57(3):649-55 (Pubitemid 16164626)
106. Wallack MK, Bash JA, Leftheriotis E, et al. Positive relationship of clinical and serologic responses to vaccinia melanoma oncolysate. Arch Surg 1987;122(12):1460-3 (Pubitemid 18058300)
107. Wallack MK, Sivanandham M, Balch CM, et al. A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 1995;75(1):34-42
108. Poland GA, Grabenstein JD, Neff JM. The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program. Vaccine 2005;23(17-18):2078-81 (Pubitemid 40341430)
109. Parker RF, Bronson LH, Green RH. Further studies of the infectious unit of vaccinia. J Exp Med 1941;74(3):263-81
110. Nalca A, Zumbrun EE. ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile. Drug Des Devel Ther 2010;4:71-9
111. Sepkowitz KA. How contagious is vaccinia? N Engl J Med 2003;348(5):439-46 (Pubitemid 36159363)
112. Merrick AE, Ilett EJ, Melcher AA. JX-594, a targeted oncolytic poxvirus for the treatment of cancer. Curr Opin Investig Drugs 2009;10(12):1372-82
113. Artenstein AW. New generation smallpox vaccines: a review of preclinical and clinical data. Rev Med Virol 2008;18(4):217-31 (Pubitemid 352018846)
114. Tysome JR, Briat A, Alusi G, et al. Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer. Gene Ther 2009;16(10):1223-33
115. Kretzschmar M, Wallinga J, Teunis P, et al. Frequency of adverse events after vaccination with different vaccinia strains. PLoS Med 2006;3(8):e272
116. Fang Q, Yang L, Zhu W, et al. Host range, growth property, and virulence of the smallpox vaccine: vaccinia virus Tian Tan strain. Virology 2005;335(2):242-51 (Pubitemid 40544913)